The term 'metabolically healthy obese (MHO)' is distinguished using body mass index (BMI), yet BMI is a poor index of adiposity. Some epidemiological data suggest that MHO carries a lower risk of cardiovascular disease (CVD) or mortality than being normal weight yet metabolically unhealthy. OBJECTIVES: We aimed to undertake a detailed phenotyping of individuals with MHO by using imaging techniques to examine ectopic fat (visceral and liver fat deposition) and myocardial function. We hypothesised that metabolically unhealthy individuals (irrespective of BMI) would have adverse levels of ectopic fat and myocardial dysfunction compared with MHO individuals. SUBJECTS: Individuals were categorised as non-obese or obese (BMI ⩾ 30 kg m − 2 ) and as metabolically healthy or unhealthy according to the presence or absence of metabolic syndrome. METHODS: Sixty-seven individuals (mean ± s.d.: age 49 ± 11 years) underwent measurement of (i) visceral, subcutaneous and liver fat using magnetic resonance imaging and proton magnetic resonance spectroscopy, (ii) components of metabolic syndrome, (iii) cardiorespiratory fitness and (iv) indices of systolic and diastolic function using tissue Doppler echocardiography. RESULTS: Cardiorespiratory fitness was similar between all groups; abdominal and visceral fat was highest in the obese groups. Compared with age-and BMI-matched metabolically healthy counterparts, the unhealthy (lean or obese) individuals had higher liver fat and decreased early diastolic strain rate, early diastolic tissue velocity and systolic strain indicative of subclinical systolic and diastolic dysfunction. The magnitude of dysfunction correlated with the number of components of metabolic syndrome but not with BMI or with the degree of ectopic (visceral or liver) fat deposition. CONCLUSIONS: Myocardial dysfunction appears to be related to poor metabolic health rather than simply BMI or fat mass. These data may partly explain the epidemiological evidence on CVD risk relating to the different obesity phenotypes.
INTRODUCTION
Obesity has been considered to confer an increased risk of cardiovascular disease (CVD) and mortality. 1, 2 However, there is increasing recognition of a subgroup of obese patients with the mechanical complications of obesity but without the associated metabolic complications: 'metabolically healthy obese' (MHO). 3 There is conflicting data in the literature regarding metabolic risk and obesity, and whether metabolic risk is determined more by the relative distribution than the absolute volume of fat. Metabolically healthy individuals have increased subcutaneous fat relative to visceral fat and lower cellular fat in liver and skeletal muscle in comparison to metabolically unhealthy individuals. 4 They are also more insulin sensitive and have a better inflammatory status. 5, 6 Several studies have demonstrated that the quantity of liver fat is more closely linked to the metabolic complications of obesity than that of visceral fat. [7] [8] [9] However, there is conflicting evidence that suggests excess visceral fat and insulin resistance, but not general adiposity are associated with incident pre-diabetes and type 2 diabetes in obese individuals. 10 A recent study of almost 30 000 individuals demonstrated that metabolically unhealthy obese individuals have a greater risk of developing diabetes than the metabolically healthy obese. 11 Although this area remains contentious, a number of epidemiological studies have demonstrated that MHO individuals are also at a lower risk of CVD, and have reduced morbidity and mortality compared with the metabolically unhealthy obese, suggesting that cardiometabolic risk factors are more strongly associated with adverse cardiovascular outcomes than obesity. [12] [13] [14] [15] [16] However, not all data suggest a protective effect. A recent study suggested that MHO confers increased risk of heart failure, but not acute myocardial infarction. 17 Similarly, the risk of developing CVD in the San Antonio Heart Study was found to be increased in MHO. 18 A recent systematic review and meta-analysis found that, after 10 years of follow-up, MHO is associated with an increased risk of total mortality and cardiovascular events.
function. Developments in echocardiographic techniques have improved the detection of relatively subtle myocardial disease. 20 Strain and strain rate are sensitive measures of change of myocardial shape (that is, deformation). Strain indicates the amount of myocardial deformation (negative strain means shortening and positive strain, elongation); strain rate, is a measure of the rate of myocardial deformation. Measurement of strain and strain rate detect pre-clinical myocardial abnormalities, which can help predict risk of cardiovascular events and mortality. 21 In patients with metabolic syndrome, subclinical left ventricular (LV) dysfunction has been detected (lower early diastolic and systolic tissue velocities accompanied by reduced strain and strain rates) compared with matched controls, worse in those with a greater number of components of the metabolic syndrome. 22, 23 Considering the influence of liver fat on metabolic health and the association of non-alcoholic fatty liver disease (NAFLD) with features of the metabolic syndrome, 24 others have looked at NAFLD patients and demonstrated subclinical myocardial systolic and diastolic dysfunction in the presence or absence of type 2 diabetes. 25, 26 The main aim of this cross-sectional study was to determine whether metabolically unhealthy individuals irrespective of their BMI or normal weight, overweight or obese category, have evidence of increased ectopic fat (with higher visceral and liver fat deposition), combined with impaired myocardial function, compared with age-and BMI-matched metabolically healthy individuals. Furthermore we hypothesised that MHO individuals would have little evidence of ectopic fat and preserved myocardial function similar to normal weight (metabolically healthy) individuals despite their overall higher fat mass. This would provide a mechanistic context for the epidemiological data around CVD risk and the different obesity phenotypes. We employed a combination of whole body magnetic resonance imaging to look at ectopic fat and sensitive echocardiographic measures to measure myocardial function.
SUBJECTS AND METHODS Subjects
Patients with hyperlipidemia and suspected NAFLD were prospectively recruited from specialist lipid and hepatology outpatient clinics at University Hospital Aintree, Liverpool. To recruit metabolically healthy, lean and obese individuals we relied on local advertisements. As the association of BMI and metabolic health with cardiac outcomes was a novel investigation, the effect size of interest was unknown. No formal sample size was calculated and recruitment of patients was based on availability with the hope that the estimates obtained will inform future studies. The study conformed to the Declaration of Helskinki and Liverpool Research Ethics Committee approved the study (Ethics Reference 09/H1005/7). All participants gave written informed consent.
Individuals aged 421 years with a BMI o40 kg m −2 who were able to walk on a treadmill and undergo magnetic resonance imaging scanning were recruited. Those with a history of CVD (including atrial fibrillation, ischaemic heart disease, heart failure or valvulopathy), type 1 or type 2 diabetes mellitus or chronic liver disease (other than NAFLD) were excluded. Individuals with a BMI 440 kg m −2 were excluded due to the technical challenges of performing high-quality echocardiographic studies on those with morbid obesity. All females and males consumed o14 and o21 units of alcohol per week, respectively. We recorded the following medications: diuretics, statins, ezetimibe, angiotensin converting enzyme inhibitors, calcium channel antagonists and beta-blockers in all participants.
Anthropometry
Age, gender, smoking status, past medical history, drug history and family history of CVD were established using a series of questionnaires. Smoking status was defined as never, former or current smoker. Physical activity levels were determined using the long format International Physical Activity Questionnaire. 27 Alcohol intake was determined using the Alcohol Use Disorders Identification Test questionnaire. 28 Blood pressure was measured on at least two separate occasions, with the patient sitting for at least 10 min. Body mass was measured after an overnight fast, without shoes, using a Tanita bioimpedance analyser, which also determined fatfree mass and fat percentage (Tanita BC420, Dolby Medical, Stirling, UK Abdominal axial T1-weighted fast spin echo scans (axial scans, 10 mm slice thickness followed by a 10 mm gap using the integrated body coil) were used to calculate abdominal visceral and subcutaneous adipose tissue. 31 A blinded researcher performed all analyses of visceral and subcutaneous fat centrally.
Liver lipid was measured non-invasively using proton magnetic resonance spectroscopy ( 1 H-MRS) as previously described. [31] [32] [33] NAFLD was defined as intrahepatocellular lipid content 45.5% measured by 1 H-MRS. Three voxels of interest were identified in the liver avoiding ducts and vasculature and the mean value taken after data were processed independently.
1 H MR spectra from liver was quantified using the AMARES algorithm in the software package jMRUI-3.0. Intrahepatocellular lipid is expressed as percentage of CH2 lipid signal amplitude relative to water signal amplitude after correcting for T1 and T2. Fat quantification by 1 H-MRS has been validated against gold standard biochemical measurements. 34 
Biochemical markers and assays
Venous blood samples were obtained from participants after an overnight fast (minimum 8 h). Serum lipid profiles, liver function and glucose were measured using standard proprietary agents using the Olympus AU2700 analyser (Beckman Coulter Ltd, High Wycombe, UK). Plasma insulin and adiponectin were measured by radioimmunoassay using commercially available kits (Millipore Corporation, Billerica, MA; intra-assay coefficient of variation 6% and 5%, respectively). All patients with NAFLD underwent a routine liver screen (antinuclear, parietal cell, mitochondrial, smooth muscle, reticulin, liver kidney microsomal type 1 and anti-centromere antibodies, ceruloplasmin and ferritin levels and hepatitis serology).
Cardiopulmonary exercise testing
Incremental cardiopulmonary exercise testing was performed on a treadmill (Model 77OCE, RAM Medisoft Group, Sorinnes, Belgium) using a modified Bruce protocol. Breath-by-breath expiratory gases and ventilation analysis were performed (Love Medical Cardiopulmonary Diagnostics, Cheshire, UK). Following a 3-min warm-up at 2.8 km h − 1 with no gradient, the initial workload was set at 2.8 km h − 1 with a 5% gradient. Thereafter, stepwise increments were made in gradient and/or speed every 3 min as per the Modified Bruce Protocol. Peak patient effort was defined by any of (i) a respiratory exchange ratio 41.1, (ii) heart rate 490% of predicted maximum, (iii) a plateau in VO 2 , or (iv) patient exhaustion. 35 Continuous electrocardiographic monitoring was used and all tests were physician-supervised.
Metabolically healthy obesity and preserved cardiac functionTrans-thoracic echocardiography image acquisition and interpretation All echocardiograms were performed using a GE Vivid 7 or E9 machine (GE, Pollards Wood, UK) with a 2.5 MHz phased array transducer and the patient in the left lateral position on a reclining couch. A combination of twodimensional, M-mode, pulsed wave and continuous wave Doppler and tissue Doppler was used. Conventional echocardiographic views were obtained (parasternal long axis, parasternal short axis, apical 4 chamber, apical long axis, apical 2 chamber and subcostal).
LV diameter and wall thicknesses were measured in the parasternal long axis view using two-dimensional or M-mode measurements. LV mass was calculated using Devereux's formula and was indexed to body surface area. 36 Modified Simpson's biplane method was used to determine LV ejection fraction. Mitral inflow velocities and deceleration times were measured using pulsed wave Doppler in the apical 4 chamber view. Isovolumetric relaxation time was calculated using continuous wave Doppler, with the cursor midway between left ventricular outflow and mitral inflow. For tissue Doppler imaging, colour tissue Doppler loops were recorded using a frame rate 4100 frames s. Myocardial longitudinal function was assessed from three consecutive cycles of tissue Doppler imaging in the apical 4 chamber, apical 2 chamber and apical long axis views.
Echocardiographic data was analysed using Echopac V9.01 (GE, Horten, Norway). Peak systolic and early and late diastolic myocardial tissue velocities were obtained from the basal segment of all six LV walls. Myocardial deformation curves were obtained from the basal segment of all the six LV walls. Wall motion was manually tracked throughout the cardiac cycle to maintain continuity of the sampling area. Data were excluded if a smooth curve was unobtainable, or if the angle between the ventricular wall and the scan line was 420°. From these curves, peak systolic strain, systolic and early and late diastolic strain rates were obtained. Using data from each of the three cardiac cycles, the values from each wall were averaged to give a mean value.
Statistical analysis
Continuous variables are presented as mean ± s.d. or median (interquartile range) if non-normally distributed; categorical variables are presented as frequencies and percentages. Univariate statistical comparisons of patient demographics between groups were conducted; for continuous variables using a one-way analysis of variance or a Kruskal-Wallis test when nonnormal; for categorical variables, using a χ 2 test or a Fisher's Exact test when cell frequencies were insufficient. P-values were corrected for multiple comparisons using Sime's procedure and declared as significant if a P-value o 0.017 was achieved.
A multiple linear regression model was fitted to investigate the association of BMI and metabolic syndrome on cardiac function. A twoway interaction of the main effects was investigated and retained if a P-value o0.1 was obtained. Sensitivity analysis was conducted, adjusting the final model for age and gender. To explore the association between cardiac function and the number of metabolic syndrome components a univariate regression model was fitted. To investigate the relative strength of each metabolic syndrome component on cardiac function, all variables were standardised. A multivariable linear regression model was fitted including the metabolic syndrome components as main effects and then adjusted for age and gender. No interactions were investigated and results are expressed as the s.d. change in cardiac function associated with a one s.d. increment in the independent variable.
The association of liver fat with cardiac function was analysed using Spearman's correlation coefficient.
Model fit was assessed using quantile-quantile (QQ) plots and standardised residuals against predicted means plots. Results were declared as significant if Po 0.05. All statistical analyses were conducted using Stata IC 13 (Stata Statistical Software: Release 13, StataCorp LP, College Station, TX, USA).
RESULTS

Clinical characteristics
Sixty-seven participants were recruited, of whom two were excluded (one with left bundle branch block on electrocardiography, one unable to tolerate MR scanning; Table 1 ). Twenty-two participants had ⩾ 3 components of the metabolic syndrome: 21 (96%) had the waist circumference component, 18 (82%) the triglyceride component, 16 (73%) the blood pressure component, 12 (55%) the HDL cholesterol component and 8 (36%) the glucose component. Tables 1 and 2 and Figure 1 show mean results in the four groups formed by the two classifications, obese vs non-obese and with (MS+) vs without (MS − ) metabolic syndrome. There Table 1 . Clinical, biochemical, metabolic and body composition characteristics of study participants Non-obese, MS − (n = 28) Non-obese, MS+ (n = 10) Obese, MS − (n = 15) Obese, MS+ (n = 12) P-value were no significant differences between the four groups in terms of age, gender, systolic blood pressure, smoking status or cardiorespiratory fitness (Table 1) . Ten-year cardiovascular risk was highest in the MS+ groups.
Higher proportions of those in the MS+ groups were taking medication for hypertension or hyperlipidaemia, reflecting the higher prevalence of these conditions. In non-obese MS − one patient was taking an angiotensin converting enzyme inhibitor, Metabolically healthy obesity and preserved cardiac functiontwo calcium channel antagonists and six statins; in non-obese MS + two were taking calcium channel antagonists, three statins, one diuretics and one ezetimibe; in obese MS − one patient was taking a statin; in obese MS+ five were taking angiotensin converting enzyme inhibitors, one calcium channel antagonists, two betablockers, four statins and one ezetimibe.
Metabolic and biochemical data There were significant differences in fasting triglyceride, HDL cholesterol and glucose concentrations between the four groups ( Table 1) . HbA1C was o4.5 in all individuals. Insulin concentrations were significantly different between groups (P = 0.002) with higher levels observed in the obese groups. There were no significant differences in adiponectin concentrations between the groups. The liver screen was negative for all patients included in the study.
Body composition data As expected, there was a significant difference in BMI across the four groups (P o 0.001; Table 1 ). The obese groups had greater subcutaneous adipose tissue and visceral adipose tissue than the non-obese groups, although there was no significant difference in their relative proportion (VAT:SAT ratio). The intrahepatocellular lipid content was up to four times higher in the metabolically unhealthy patients in comparison to the metabolically healthy, however the difference across groups did not reach statistical significance (P = 0.055).
Echocardiographic data In terms of LV morphology, there were no significant differences across the groups in LV mass, posterior wall thickness, LV mass indexed to body surface area, LV septal wall thickness or LV internal diastolic diameter (Table 2 ). In terms of LV systolic function, LV ejection fraction, systolic tissue velocity (Sʹ) and peak systolic longitudinal strain rate did not differ significantly across the groups, however, there was a significant difference in peak systolic (longitudinal) strain (P = 0.001; Table 2 and Figure 1a ). Linear regression showed that patients with MS had significantly lower peak systolic strain than those without (Δ = − 2.45: 95% confidence interval (CI) − 3.74, − 1.15; P o 0.001), with a progressive reduction in peak systolic strain as the number of MS components increased (Figure 2a and Table 4A ). Of the metabolic syndrome components, triglycerides were significantly associated with peak systolic strain (for a one s.d. increase: − 0.29: 95% CI − 0.53, − 0.04; P = 0.021; Table 4B ).
A higher BMI was associated with a lower peak systolic strain (for a unit increase in BMI, Δ = − 0.12: 95% CI − 0.24, − 0.004; P = 0.043; Table 3 ). No significant interaction was found between BMI and metabolic health. Peak systolic strain was significantly inversely correlated with liver fat (Ρ = − 0.35; P = 0.0042) but not with VAT:SAT ratio (Ρ = − 0.12; P = 0.36).
In terms of LV diastolic function, left atrial size and E/Eʹ ratio were not significantly different across the groups (Table 2) . Early (Eʹ) and late (Aʹ) diastolic tissue velocity and early diastolic strain rate (EDSR) were significantly different between groups (all P o0.01) with lower levels observed for the metabolically unhealthy. Linear regression showed that patients with metabolic syndrome had significantly lower Eʹ (−1.89: 95% CI − 2.73, − 1.06; P o0.001) and EDSR (−0.28: 95% CI: − 0.41, − 0.15; P o 0.001) with a progressive reduction occurring in both cardiac parameters as the number of metabolic syndrome components increased (Figure 2b and c; Table 4A and B). Of the metabolic syndrome components, glucose was significantly associated with early diastolic tissue velocity (for a one s.d. increase: − 0.30: 95% CI − 0.54, − 0.07; P = 0.012) (Table 4A and B) and systolic blood pressure was significantly associated with EDSR (for a one s.d. increase: − 0.44: 95% CI − 0.76, − 0.11; P = 0.01; Table 4A and B).
As to the feasibility and reproducibility of echocardiography, for tissue velocity, global peak systolic strain (%) and strain rate (s − 1 ), the intra-observer and inter-observer variability was 0.3 ± 0.3, 1.3 ± 0.5%, 0.1 ± 0.1 s − 1 and 0.4 ± 0.3, 1.2 ± 0.8% and 0.3 ± 0.2 s − 1 , respectively. Despite care taken during image acquisition, it was not possible to analyse 8% of left ventricular segments due to artefact and signal noise.
DISCUSSION
This integration of detailed MRI and MRS analysis of body composition, echocardiographic assessment of myocardial function and evaluation of metabolic health has provided an opportunity to compare the determinants of myocardial function in four distinct phenotypes: non-obese, mean age and BMImatched metabolically healthy and metabolically unhealthy individuals (non-obese MS − and MS+, respectively) and obese, mean age and BMI-matched metabolically healthy and metabolically unhealthy individuals (obese MS − and MS+, respectively). We find that subclinical impairment of myocardial function is more closely associated with adverse metabolic health than with either obesity or BMI. Echocardiographic measures of both diastolic and systolic myocardial function were reduced in the metabolically unhealthy vs healthy groups, irrespective of obesity. We also find that metabolic health is more closely associated with increased liver fat than visceral fat deposition suggesting fat distribution is pivotal. These observational data help provide mechanistic insight into the pathophysiology of (obesity-related) CVD and potentially support the epidemiological observations of differential cardiovascular outcomes among metabolically healthy and unhealthy, lean and obese individuals.
There is evidence from transgenic animal and human models that the capacity of SAT to expand with over-feeding determines to what extent excess lipids 'spill over' into ectopic sites (for example, skeletal muscle, liver and cardiac muscle), and therefore whether obesity is metabolically healthy or unhealthy. 37, 38 However, there is currently no consensus on how to define metabolic health or metabolically healthy obesity except for the inclusion of obesity (BMI 430 kg m − 2 ) as a criterion. Some studies use the number of components of the MS, although with different diagnostic criteria. 39 Others have used measures of insulin resistance, with inconsistencies in definitions or diagnostic criteria (use of HOMA-IR, Matsuda index derived from an oral glucose tolerance test or from the glucose disposal rate). Several studies have used measures of inflammation including C-reactive protein measurements. Large variations in reported prevalence of MHO (that is, our obese MS − group) are a function of the varied criteria used to define this phenotype. 39 Examining the impact of metabolic health on myocardial function, Seo et al. 22 and Wong et al. 23 have demonstrated subclinical left ventricular dysfunction in patients with an increased metabolic burden compared with control groups. However these studies provide no data on different body composition phenotypes.
Our findings are consistent with several large-scale epidemiological studies suggesting that metabolically healthy (obese and non-obese) individuals have a lower risk of CVD than metabolically unhealthy (obese and non-obese) individuals 12, 13, 15 although this is not universally agreed. 18, 19 Morkedal et al. 17 have demonstrated disparate effects on coronary heart disease and heart failure, which may account for the contrasting conclusions. 40 There are several potential mechanisms whereby metabolically unhealthy individuals may have impaired myocardial performance. The metabolically unhealthy group tended to have higher intrahepatocellular lipid content. Previous studies demonstrated that NAFLD is associated with increased levels of both intrapericardial and extra-pericardial fat, which may adversely influence cardiac metabolism. [41] [42] [43] Thus metabolically unhealthy patients may also have increased liver and intra-myocardial triglyceride, leading to lipotoxicity and apoptosis of cardiac myocytes, potentially contributing to myocardial dysfunction. 44 However, in our study the difference in liver triglyceride did not reach statistical significance and we did not measure cardiac triglyceride. Metabolically unhealthy individuals have increased levels of inflammatory markers (interleukins, tumour necrosis factor-alpha and high-sensitivity CRP), which can result in cardiac fibrosis and myocardial stiffening 45, 46 and increased circulating levels of the liver-secreted glycoprotein fetuin A that further induces subclinical inflammation and perturbs lipid and glucose metabolism. 6, 47 Hyperinsulinaemia and/or insulin resistance may also be implicated through abnormal LV energy metabolism; 41 indeed the cardiovascular benefit derived from bariatric surgery was strongly associated with reduced fasting insulin concentration. 48 It has been suggested the protective effect of MHO on outcomes may be due to higher levels of cardiorespiratory fitness but we found no evidence to support this. 49 These findings may have therapeutic implications. Diastolic myocardial abnormalities are associated with an increased risk of cardiovascular events and cardiac and all-cause mortality. 50, 51 Early detection of myocardial dysfunction may provide an opportunity for patients to modify their lifestyles, thereby affording the opportunity for primary prevention and reducing mortality risk. In the SOS (Swedish Obese Subjects) trial, a prospective, controlled, long-term study of bariatric surgery in Metabolically healthy obesity and preserved cardiac functionmorbidly obese people, weight loss significantly improved cardiovascular outcomes. 48 Obesity is of course associated with a variety of other medical complications besides type 2 diabetes and CVD, not related to metabolic health but caused by the mechanical consequences of obesity, for example, obstructive sleep apnoea or lower limb osteoarthritis or by so far unknown mechanisms, for example, the association with certain types of cancer. Furthermore, there are significant functional and psychological sequelae of obesity, which are again unrelated to metabolic health. However these findings would indicate that preventative strategies in obesity must be driven by diseasespecific end points (metabolic, mechanical and functional end points) rather than simply driven quantitatively by weight loss.
The study has several limitations. Due to the small group sizes for the metabolic analysis, it was not possible to calculate robust estimates. Furthermore, the small sample size also led to large variability within the measurements. However the sample size is large enough to observe clinically and statistically significant differences between the groups. It must be noted that our cohort sampling strategy may have led to a bias in the metabolically unhealthy cohort towards an abnormal phenotype that is predisposed to myocardial functional abnormalities as these patients required specialist care. Likewise, recruitment of 'healthy participants' from the community may have exaggerated the bias away from the null with 'healthy volunteer' bias. A further limitation is the possibility that a proportion of our participants may have undiagnosed atherosclerotic disease, contributing to the apparent myocardial abnormalities. However, it was not feasible to undertake coronary angiography or myocardial functional imaging in our participants to completely exclude silent coronary artery disease but all patients were screened with clinical assessment, echocardiography and exercise electrocardiography for evidence of coronary artery disease. We were also unable to measure serum fetuin A concentrations or markers of inflammation due to sample volume limitations.
CONCLUSION
The metabolic sequelae associated with unhealthy obesity appear to underlie the functional abnormalities in myocardial systolic and diastolic function, so metabolically healthy obese subjects have normal myocardial performance. This finding may help explain the epidemiological associations of metabolically healthy obesity with lower cardiovascular morbidity and mortality.
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